Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.58 |
| ▸ | ITGAV | P06756 | 15/20 | 0.56 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.56 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.56 |
| ▸ | ITGB5 | P18084 | 8/20 | 0.56 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.51 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12547669 | 0.93 | ITGB3 (0.55) | ITGB3ITGA2BITGAVITGA5ITGB1 | |
| SCHEMBL13107808 | 0.93 | ITGB3 (0.55) | ITGB3ITGA2BITGAVITGA5ITGB1 | |
| SCHEMBL21475019 | 0.93 | ITGB3 (0.55) | ITGB3ITGA2BITGAVITGA5ITGB1 | |
| SCHEMBL12808284 | 0.93 | ITGB3 (0.55) | ITGB3ITGA2BITGAVITGA5ITGB1 | |
| SCHEMBL14885799 | 0.93 | ITGB3 (0.55) | ITGB3ITGA2BITGAVITGA5ITGB1 | |
| SCHEMBL19605481 | 0.93 | ITGB3 (0.55) | ITGB3ITGA2BITGAVITGA5ITGB1 | |
| SCHEMBL7743878 | 0.93 | ITGB3 (0.55) | ITGB3ITGA2BITGAVITGA5ITGB1 | |
| SCHEMBL7743533 | 0.93 | ITGB3 (0.55) | ITGB3ITGA2BITGAVITGA5ITGB1 | |
| SCHEMBL16946584 | 0.93 | ITGB3 (0.55) | ITGB3ITGA2BITGAVITGA5ITGB1 | |
| SCHEMBL18968795 | 0.93 | ITGB3 (0.55) | ITGB3ITGA2BITGAVITGA5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179446-B2 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-6537520-B1 | Diagnosis and treatment of cancer; kit containing compound having peptide or peptidomimetic functionality that binds to a alpha v beta 3 receptor linked to a chelator | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-03-25 | — | — | US | disclosed |